Bristol-Myers Squibb stops cancer drug trial early due to positive performance

Bristol-Myers Squibb has announced that its CheckMate-214 study cancer study is set to be halted early.

The phase III study is evaluating a combination of Opdivo and Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma, with the regimen demonstrating superior overall survival in intermediate and poor-risk patients.

It meant that the regimen met its primary efficacy endpoint, while the combination also met its secondary endpoint of improved overall survival across all randomised patients.

Based on a planned interim analysis of the findings, an independent data monitoring committee has recommended that the trial be stopped early.

Dr Vicki Goodman, head of new asset development at Bristol-Myers Squibb, said: "This overall survival result from CheckMate-214 highlights the potential of the combination of Opdivo and Yervoy to provide a new treatment option for first-line advanced renal cell carcinoma patients, for whom there is a considerable unmet need."

Results from this study will be shared with regulatory authorities and presented by the company at the European Society for Medical Oncology Congress.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.